Canaccord Genuity raises Seres Therapeutics stock price target to $22 on FDA hopes

Canaccord Genuity significantly raised its price target for Seres Therapeutics (NASDAQ: MCRB) to $22.00 from $14.00, maintaining a Buy rating, driven by positive FDA feedback and increased probability of approval for its products, notably the SER-155 program which holds Breakthrough Therapy designation. Despite reporting a larger-than-expected Q2 2025 loss, the company projects a cash runway into Q2 2026, supported by existing cash and an anticipated $25 million payment from Nestle, as it actively seeks capital to advance its key therapeutic initiatives.

Analysis

Seres Therapeutics (MCRB) presents a classic high-risk, high-reward biotech profile, underscored by conflicting data points. On the positive side, Canaccord Genuity has significantly raised its price target to $22.00 from $14.00, maintaining a 'Buy' rating, citing increased confidence in FDA approval for the company's pipeline. This optimism is centered on the SER-155 program, which has received Breakthrough Therapy designation and constructive FDA feedback on its Phase 2 protocol. The company's financial runway is projected to extend into Q2 2026, supported by approximately $45.4 million in cash and an expected $25 million payment from Nestle in Q3 2025. However, this bullish outlook is sharply contrasted by a substantial Q2 2025 earnings miss, where the reported loss per share of -$2.27 was dramatically worse than the -$0.09 forecast. Furthermore, despite the sale of VOWST and the projected cash runway, the company is actively seeking additional capital to advance the SER-155 study, highlighting a near-term funding risk. The outcome of a search for a strategic partner also remains a key unknown variable.

Key Decisions for Investors

• Investors should weigh the significant catalyst potential from the SER-155 program, which has FDA Breakthrough Therapy designation, against the considerable financial risk highlighted by the recent large earnings miss and the stated need to raise more capital.
• Monitor for key upcoming milestones that could de-risk the investment, including the finalization of the SER-155 Phase 2 protocol, the securing of a strategic partner, and the terms of any future capital raise, as a dilutive offering could create a headwind for the stock.
• Given the stock price at $17.56 is already approaching the new analyst high target of $22, it may be prudent to await a more favorable entry point or confirmation of successful capital raising before initiating or adding to a position.